RESUMEN
A uncommon inflammatory condition called morphea causes fibrosis in the skin and subcutaneous tissue. The key stages in the pathophysiology are vascular damage, immunological response, and fibrosis. Numerous research have examined the relationships between the immune system, fibrosis, and vitamin D, but the exact pathogenetic pathways of morphea remain poorly understood. The purpose of this study was to investigate serum 25(OH)D levels and the ApaI (rs7975232) and TaqI (rs731236) polymorphisms of the vitamin D receptor (VDR) in morphea patients. There were 48 age- and sex-matched controls and 41 morphea patients total. VDR polymorphisms were found using PCR tests and gel electrophoresis, and serum 25(OH)D levels were determined using liquid chromatography combined with tandem mass spectrometry (LC-MS/MS). The patient group consisted of 37 females (90.2%) and 4 males (9.8%). The patients' mean age was 38.68 ± 17.54 years. In terms of VDR ApaI and TaqI polymorphisms, there was no discernible difference between the patient and control groups. TaqI polymorphism heterozygosity was discovered in all patients with progressive disease, and this finding was statistically significant (p = 0.012). Patients' mean serum 25(OH)D levels were 16.98 ± 11.55 ng/mL, while those in the control group were 18.02 ± 14.30 ng/mL. VDR polymorphisms, vitamin D levels, disease subtype, age of onset, and responsiveness to treatment did not significantly correlate. In our research, we discovered that TaqI polymorphism may be related to the severity of the disease and that the polymorphisms of the VDR ApaI and TaqI were not associated with morphea susceptibility.
Asunto(s)
Polimorfismo Genético , Receptores de Calcitriol , Esclerodermia Localizada , Vitamina D , Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Estudios de Casos y Controles , Vitamina D/sangre , Receptores de Calcitriol/genética , Esclerodermia Localizada/sangre , Esclerodermia Localizada/genética , Esclerodermia Localizada/fisiopatología , Gravedad del Paciente , TurquíaRESUMEN
BACKGROUND: Scleroderma en coup de sabre (ECDS) and Parry-Romberg idiopathic hemifacial atrophy (IHA) may affect the eyes, oral cavity, teeth and possibly the brain. OBJECTIVE: Systematic follow-up study of ECDS/IHA-associated manifestations including ophthalmic and dental status. METHODS: Medical records of ECDS and IHA patients diagnosed in a 40-year period (1975-2015) were reviewed, and patients were re-examined. RESULTS: Thirty-five patients were included. Twenty-two patients (63%) had ECDS and 4 patients (11%) IHA. In 9 cases (26%), ECDS and IHA were found in the same patient. The ipsilateral eye was affected in 9 patients (26%). Ipsilateral abnormalities of the teeth and the tongue were found in 13 (46%) out of 28 examined. Eleven (31%) had extrafacial scleroderma on the trunk or the extremities. Neurological findings were not verified as ECDS/IHA related. CONCLUSION: ECDS and IHA are related and often overlap with concomitant affections of the connective tissues of the face on the ipsilateral side. Ocular and dental abnormalities are common and follow the distribution of the primary affection, for example, a paramedian line in the front and segmental affection of the maxilla and the mandible. The affections point to predisposing dysmorphogenetic events in embryonal life affecting the face, with abnormality of crest cells at the stage when they migrate from behind over the scalp or laterally to the face to mix up with mesenchymal tissues of the frontonasal, maxillary and mandibular processes. The study emphasizes that routine evaluation of ECDS and IHA should include ophthalmological and dental specialist examinations.
Asunto(s)
Oftalmopatías/etiología , Hemiatrofia Facial/complicaciones , Esclerodermia Localizada/complicaciones , Anomalías Dentarias/etiología , Adolescente , Adulto , Anticuerpos Antinucleares/sangre , Niño , Preescolar , Anomalías del Ojo/etiología , Hemiatrofia Facial/sangre , Femenino , Estudios de Seguimiento , Humanos , Lactante , Masculino , Esclerodermia Localizada/sangre , Lengua/anomalías , Adulto JovenRESUMEN
OBJECTIVES: Vasculopathy is an important hallmark of systemic chronic inflammatory connective tissue diseases (CICTD) and is associated with increased cardiovascular risk. We investigated disease-specific biomarker profiles associated with endothelial dysfunction, angiogenic homeostasis and (tissue) inflammation, and their relation to disease activity in rare CICTD. METHODS: A total of 38 serum proteins associated with endothelial (dys)function and inflammation were measured by multiplex-immunoassay in treatment-naive patients with localized scleroderma (LoS, 30), eosinophilic fasciitis (EF, 8) or (juvenile) dermatomyositis (34), 119 (follow-up) samples during treatment, and 65 controls. Data were analysed by unsupervised clustering, Spearman correlations, non-parametric t test and ANOVA. RESULTS: The systemic CICTD, EF and dermatomyositis, had distinct biomarker profiles, with 'signature' markers galectin-9 (dermatomyositis) and CCL4, CCL18, CXCL9, fetuin, fibronectin, galectin-1 and TSP-1 (EF). In LoS, CCL18, CXCL9 and CXCL10 were subtly increased. Furthermore, dermatomyositis and EF shared upregulation of markers related to interferon (CCL2, CXCL10), endothelial activation (VCAM-1), inhibition of angiogenesis (angiopoietin-2, sVEGFR-1) and inflammation/leucocyte chemo-attraction (CCL19, CXCL13, IL-18, YKL-40), as well as disturbance of the Angiopoietin-Tie receptor system and VEGF-VEGFR system. These profiles were related to disease activity, and largely normalized during treatment. However, a subgroup of CICTD patients showed continued elevation of CXCL10, CXCL13, galectin-9, IL-18, TNFR2, VCAM-1, and/or YKL-40 during clinically inactive disease, possibly indicating subclinical interferon-driven inflammation and/or endothelial dysfunction. CONCLUSION: CICTD-specific biomarker profiles revealed an anti-angiogenic, interferon-driven environment during active disease, with incomplete normalization under treatment. This warrants further investigation into monitoring of vascular biomarkers during clinical follow-up, or targeted interventions to minimize cardiovascular risk in the long term.
Asunto(s)
Biomarcadores/sangre , Dermatomiositis , Endotelio Vascular/inmunología , Eosinofilia , Fascitis , Esclerodermia Localizada , Autoinmunidad , Quimiocina CXCL10/sangre , Quimiocina CXCL13/sangre , Dermatomiositis/sangre , Dermatomiositis/diagnóstico , Eosinofilia/sangre , Eosinofilia/diagnóstico , Fascitis/sangre , Fascitis/diagnóstico , Femenino , Galectinas/sangre , Factores de Riesgo de Enfermedad Cardiaca , Humanos , Masculino , Persona de Mediana Edad , Monitorización Inmunológica/métodos , Países Bajos , Gravedad del Paciente , Receptores Tipo II del Factor de Necrosis Tumoral/sangre , Esclerodermia Localizada/sangre , Esclerodermia Localizada/diagnóstico , Molécula 1 de Adhesión Celular Vascular/sangreAsunto(s)
Dermatomiositis/epidemiología , Eosinofilia/epidemiología , Fascitis/epidemiología , Inhibidores de Puntos de Control Inmunológico/efectos adversos , Lupus Eritematoso Cutáneo/epidemiología , Esclerodermia Localizada/epidemiología , Anciano , Anticuerpos Antinucleares/sangre , Anticuerpos Antinucleares/inmunología , Dermatomiositis/sangre , Dermatomiositis/inducido químicamente , Dermatomiositis/inmunología , Eosinofilia/sangre , Eosinofilia/inducido químicamente , Eosinofilia/inmunología , Fascitis/sangre , Fascitis/inducido químicamente , Fascitis/inmunología , Femenino , Humanos , Lupus Eritematoso Cutáneo/sangre , Lupus Eritematoso Cutáneo/inducido químicamente , Lupus Eritematoso Cutáneo/inmunología , Masculino , Persona de Mediana Edad , Neoplasias/tratamiento farmacológico , Neoplasias/inmunología , Estudios Retrospectivos , Esclerodermia Localizada/sangre , Esclerodermia Localizada/inducido químicamente , Esclerodermia Localizada/inmunologíaRESUMEN
Localized scleroderma (LoSc) is a rare disease manifested by an inflammation and sclerosis of the skin. The latest studies focused on glycoprotein Krebs von den Lungen-6, surfactant protein-D, chemokine ligand 18 and dipeptidylpeptidase 4 as potential biomarkers of skin fibrosis in systemic scleroderma. Our study aimed to identify 6 miRNAs with elevated or decreased levels in 38 LoSc patients (31 females, 7 males) compared to healthy volunteers (HVs) and to correlate the selected miRNAs' serum levels with the severity and the clinical symptoms of LoSc and some laboratory parameters with the selected miRNAs' serum levels. The serum levels of miRNAs, i.e. miRNA-181b-5p, miRNA-223-3p, miRNA-21-5p, let 7i-5p, miRNA-29a-3p and miRNA-210-3p were significantly increased in the LoSc patients compared to the HVs. The level of let-7i increase in the female LoSc patients correlated negatively with BSA (r = - 0.355, p = 0.049) and mLoSSI (r = - 0.432, p = 0.015). Moreover, the female patients with inactive LoSc had significantly higher level of let-7i (2.68-fold on average) in comparison to those with active disease (p = 0.045). The exact role of those molecules has not been revealed in LoSc and a long-term longitudinal research is pivotal to confirm their prognostic value.
Asunto(s)
Biomarcadores/sangre , MicroARN Circulante/sangre , Perfilación de la Expresión Génica/métodos , Esclerodermia Localizada/genética , Adulto , Anciano , Estudios de Casos y Controles , Femenino , Humanos , Masculino , MicroARNs/sangre , Persona de Mediana Edad , Pronóstico , Esclerodermia Localizada/sangre , Índice de Severidad de la Enfermedad , Caracteres Sexuales , Regulación hacia ArribaRESUMEN
OBJECTIVES: Clinical and laboratory investigations have revealed that Epstein-Barr virus (EBV) is involved in altered immunological response of systemic lupus erythematosus (SLE). Higher seroprevalence rates of anti-EBV antibodies and increased viral load are demonstrated in adult SLE patients. The prevalence of BK polyomavirus (BKV) reactivation is also suggested to be higher in SLE. Herein, we aimed to evaluate the immune response of children with SLE to EBV antigens in addition to EBV and BKV DNA. We also tried to evaluate whether these serological results differ from another connective tissue disease - juvenile systemic sclerosis (jSS) - and healthy individuals. METHODS: Serum levels of EBV early antigen diffuse (EA-D) IgG, EBV nuclear antigen-1 IgG, EBV viral capsid antigen (VCA), cytomegalovirus (CMV) IgG, EBV DNA, CMV DNA and urinary BKV DNA were evaluated in healthy controls and in patients with a diagnosis of juvenile SLE (jSLE) and jSS. RESULTS: A total of 70 jSLE patients, 14 jSS patients and 44 sex-matched healthy individuals were involved in the study. EBV VCA was positive in 84.2% of jSLE patients, 85.7% of jSS patients and 36.3% of healthy controls. EBV EA-D IgG positivity was significantly higher in jSLE patients compared to jSS patients and healthy controls (20% vs. 7.1% and 0%, p = 0.005). EBV VCA positivity was associated with malar rash and immunological disorder, but there was no statistical significance in other antibody positivity in terms of clinical and haemogram findings and autoantibody positivity. CMV DNA positivity was present in only 2.8% of jSLE patients. None of the jSS patients or the healthy controls had CMV DNA positivity. EBV DNA and BKV DNA were also negative in all three groups. CONCLUSION: The results of our study assume a relationship between SLE and EBV, but we could not demonstrate an association between CMV and BKV. The negative DNA results in contrast to serological positivity can be interpreted as an altered and impaired immune system and increased viral susceptibility. These results suggest that EBV contributes to disease continuity, even if it does not directly cause development.
Asunto(s)
Herpesvirus Humano 4/inmunología , Lupus Eritematoso Sistémico/virología , Adolescente , Adulto , Anticuerpos Antivirales/sangre , Antígenos Virales/sangre , Antígenos Virales/inmunología , Virus BK/inmunología , Virus BK/aislamiento & purificación , Proteínas de la Cápside/inmunología , Estudios de Casos y Controles , Niño , Citomegalovirus/inmunología , Citomegalovirus/aislamiento & purificación , Progresión de la Enfermedad , Infecciones por Virus de Epstein-Barr , Herpesvirus Humano 4/aislamiento & purificación , Humanos , Lupus Eritematoso Sistémico/sangre , Esclerodermia Localizada/sangre , Esclerodermia Localizada/virología , Esclerodermia Sistémica/sangre , Esclerodermia Sistémica/virología , Carga Viral , Adulto JovenRESUMEN
Linear scleroderma is a variant of localized scleroderma. We report a 43-year-old woman who had developed left arm weakness and linear scleroderma on her back during pregnancy at 25 years of age, followed by left hemifacial atrophy and left leg weakness. She had multiple linear scleroderma lesions on her trunk and left limbs, left eyelid ptosis, impairment of vertical movement and abduction of the left eye, left hemifacial atrophy, and weakness and atrophy of the sternocleidomastoid, trapezius, and proximal limb muscles on the left side. On serology, antibodies to U1-ribonucleoprotein and Jo-1 were positive; anti-scleroderma-70 antibody was negative. Skin biopsy demonstrated increased hypertrophic collagen fibers without inflammatory infiltrates. Needle electromyography of left limb muscles revealed mild neurogenic patterns; left quadriceps muscle biopsy showed chronic neurogenic changes. Brain magnetic resonance imaging revealed mild left hemispheric atrophy. This is a rare case of linear scleroderma and Parry-Romberg syndrome presenting with widespread ipsilateral neurogenic manifestations.
Asunto(s)
Hemiatrofia Facial/complicaciones , Hemiatrofia Facial/diagnóstico por imagen , Esclerodermia Localizada/complicaciones , Esclerodermia Localizada/diagnóstico por imagen , Adulto , Diagnóstico Diferencial , Hemiatrofia Facial/sangre , Femenino , Humanos , Esclerodermia Localizada/sangreRESUMEN
Connective tissue diseases often prominently affect the skin, requiring dermatologists to play an important role in diagnosis and treatment of these patients. Herein we describe updates on the pathogenesis, clinical features, and treatment of 4 major connective tissue diseases: dermatomyositis, cutaneous lupus erythematosus, limited scleroderma (morphea), and cutaneous vasculitis. Many of these updates promise to improve clinical care of patients who suffer from dermatologic involvement of these diseases and are the result of research performed by dermatologists who have expertise in these conditions.
Asunto(s)
Dermatomiositis/clasificación , Dermatomiositis/tratamiento farmacológico , Lupus Eritematoso Cutáneo/tratamiento farmacológico , Esclerodermia Localizada/terapia , Antimaláricos/uso terapéutico , Biomarcadores/sangre , Humanos , Vasculitis por IgA/diagnóstico , Lupus Eritematoso Cutáneo/fisiopatología , Esclerodermia Localizada/sangre , Esclerodermia Localizada/clasificación , Enfermedades Cutáneas Vasculares/clasificación , Enfermedades Cutáneas Vasculares/diagnóstico , Enfermedades Cutáneas Vasculares/tratamiento farmacológico , Vasculitis/clasificación , Vasculitis/diagnóstico , Vasculitis/tratamiento farmacológicoRESUMEN
BACKGROUND: Localized scleroderma (LS) is an autoimmune condition of the skin and underlying tissue. Active or recurring disease can lead to cumulative tissue damage, especially in paediatric-onset disease. OBJECTIVES: To highlight the rate of relapse of LS activity in a cohort of paediatric patients and to evaluate for potential clinical and laboratory predictors of disease relapse. METHODS: Clinical and laboratory data were gathered prospectively. Patients were categorized as experiencing relapse or not, and clinical and laboratory parameters were compared. A logistic regression was fit to predict odds of relapse while controlling for multiple predictors. A subgroup of patients was also evaluated to determine the average time from treatment completion to relapse. RESULTS: Seventy-seven patients were followed for the identified study duration of > 2 years and had achieved disease remission, with 35 (45%) experiencing LS relapse. Patients who were older at disease onset, antinuclear antibody (ANA) positive and without an extracutaneous manifestation (ECM) were more likely to relapse. All three variables remained significant in the multivariable logistic regression model. Results of the subgroup mirrored the larger sample. The average time between treatment completion and relapse was 21 months. CONCLUSIONS: Assessment of patients with LS experiencing a relapse of disease activity has shown older age of initial LS onset and ANA positivity to be potential markers for risk of relapse. Patients meeting these parameters may require greater clinical vigilance. The presence of one or more ECM may be protective. Clinicians treating patients with LS should provide significant long-term follow-up to monitor for relapse.
Asunto(s)
Anticuerpos Antinucleares/sangre , Cumplimiento de la Medicación/estadística & datos numéricos , Esclerodermia Localizada/diagnóstico , Adolescente , Edad de Inicio , Anticuerpos Antinucleares/inmunología , Niño , Preescolar , Estudios de Cohortes , Progresión de la Enfermedad , Femenino , Glucocorticoides/uso terapéutico , Humanos , Masculino , Metotrexato/uso terapéutico , Pronóstico , Estudios Prospectivos , Recurrencia , Sistema de Registros/estadística & datos numéricos , Inducción de Remisión/métodos , Estudios Retrospectivos , Esclerodermia Localizada/sangre , Esclerodermia Localizada/tratamiento farmacológico , Esclerodermia Localizada/inmunologíaRESUMEN
BACKGROUND: Localized scleroderma is a chronic inflammatory skin disease characterized by sclerosis of the dermis and subcutaneous tissue. Platelets play an important role in inflammation. Following activation, platelets rapidly release numerous mediators and cytokines, which contribute to inflammation. OBJECTIVES: To evaluate whether there was any relation between localized scleroderma and platelet parameters. METHODS: Forty-one patients with localized scleroderma were enrolled in the study. The control group consisted of 30 healthy subjects. RESULTS: The mean platelet volume level in the patient group was 9.9 ± 1.3 fl and in the control group was 7.6 ± 1.1 fl. This difference was statistically significant (p< 0.001). The plateletcrit values are minimally higher in the patient group as compared to the control group. It was statistically significant (p<0.001). There was no significant difference in the platelet counts between the two groups (p= 0.560) In the patient group, there was no significant relation between the mean platelet volume levels and clinical signs of disease (p=0.09). However, plateletcrit values are higher in generalized than localized forms of disease (p=0.01). STUDY LIMITATIONS: The limited number of patients and the retrospective nature of the study were our limitations. CONCLUSIONS: This study suggests that platelets might play a role in the pathogenesis of scleroderma. Platelet parameters may be used as markers for evaluating disease severity and inflammatory processes. Thus, there is a need for more detailed and prospective studies.
Asunto(s)
Volúmen Plaquetario Medio , Esclerodermia Localizada/sangre , Adolescente , Adulto , Biomarcadores , Estudios de Casos y Controles , Niño , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
Abstract: Background: Localized scleroderma is a chronic inflammatory skin disease characterized by sclerosis of the dermis and subcutaneous tissue. Platelets play an important role in inflammation. Following activation, platelets rapidly release numerous mediators and cytokines, which contribute to inflammation. Objectives: To evaluate whether there was any relation between localized scleroderma and platelet parameters. Methods: Forty-one patients with localized scleroderma were enrolled in the study. The control group consisted of 30 healthy subjects. Results: The mean platelet volume level in the patient group was 9.9 ± 1.3 fl and in the control group was 7.6 ± 1.1 fl. This difference was statistically significant (p< 0.001). The plateletcrit values are minimally higher in the patient group as compared to the control group. It was statistically significant (p<0.001). There was no significant difference in the platelet counts between the two groups (p= 0.560) In the patient group, there was no significant relation between the mean platelet volume levels and clinical signs of disease (p=0.09). However, plateletcrit values are higher in generalized than localized forms of disease (p=0.01). Study Limitations: The limited number of patients and the retrospective nature of the study were our limitations. Conclusions: This study suggests that platelets might play a role in the pathogenesis of scleroderma. Platelet parameters may be used as markers for evaluating disease severity and inflammatory processes. Thus, there is a need for more detailed and prospective studies.
Asunto(s)
Humanos , Masculino , Femenino , Niño , Adolescente , Adulto , Persona de Mediana Edad , Adulto Joven , Esclerodermia Localizada/sangre , Volúmen Plaquetario Medio , Biomarcadores , Estudios de Casos y ControlesRESUMEN
IFN-related pathways have not been studied in morphea, and biomarkers are needed. We sought to characterize morphea serum cytokine imbalance and IFN-related gene expression in blood and skin to address this gap by performing a case-control study of 87 participants with morphea and 26 healthy control subjects. We used multiplexed immunoassays to determine serum cytokine concentrations, performed transcriptional profiling of whole blood and lesional morphea skin, and used double-staining immunohistochemistry to determine the cutaneous cellular source of CXCL9. We found that CXCL9 was present at increased concentrations in morphea serum (P < 0.0001), as were other T helper type 1 cytokines. CXCL9 serum concentration correlated with the modified Localized Scleroderma Skin Severity Index (r = 0.44, P = 0.0001), a validated measure of disease activity. CXCL9 gene expression was also increased in inflammatory lesional morphea skin (fold change = 30.6, P = 0.006), and preliminary transcriptional profiling showed little evidence for IFN signature in whole blood. Double-staining immunohistochemistry showed CXCL9 co-localized with CD68+ dermal macrophages. In summary, inflammatory morphea is characterized by T helper type 1 cytokine imbalance in serum, particularly CXCL9, which is associated with disease activity. CXCL9 expression in lesional macrophages implicates the skin as the source of circulating cytokines. CXCL9 is a promising biomarker of disease activity in morphea.
Asunto(s)
Quimiocina CXCL9/genética , Citocinas/sangre , Regulación de la Expresión Génica , ARN/genética , Esclerodermia Localizada/genética , Biomarcadores/sangre , Quimiocina CXCL9/biosíntesis , Femenino , Estudios de Seguimiento , Humanos , Inmunohistoquímica , Macrófagos/metabolismo , Macrófagos/patología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Esclerodermia Localizada/sangre , Esclerodermia Localizada/diagnóstico , Índice de Severidad de la EnfermedadRESUMEN
The levels of 63 cytokines, chemokines, and growth factors were measured in the serum of four patients with idiopathic morphea and of one patient with vitamin K1-induced morphea employing a multiplex assay to identify the role of inflammatory/immunologic events in their pathogenesis. Full-thickness skin biopsies of affected skin were analyzed by histopathology. Luminex assays for 63 cytokines, chemokines, and growth factors were performed in the sera from four patients with idiopathic morphea and in two different samples of serum obtained in two separate occasions from one patient with vitamin K1-induced morphea. The serum values of numerous inflammatory cytokines and growth factors including IL-2, IL-4, IL-6, and IFNß were markedly increased in the serum of patients with idiopathic morphea, whereas, these values were normal in the serum of the patient with vitamin K1-induced morphea. In contrast, serum eotaxin levels were greater than threefold higher in the patient with vitamin K1-induced morphea compared to patients with idiopathic morphea. The results demonstrated remarkable increases in the levels of numerous cytokines and chemokines in the serum samples of all patients with idiopathic morphea indicative of a prominent role of inflammatory/immunologic events in its pathogenesis. The results also showed statistically significant differences between idiopathic morphea and vitamin K1-induced morphea suggesting that their development involves different pathogenetic mechanisms.
Asunto(s)
Quimiocinas/sangre , Citocinas/sangre , Esclerodermia Localizada/sangre , Piel/patología , Vitamina K 1/efectos adversos , Anciano , Biomarcadores/sangre , Biopsia , Femenino , Humanos , Inyecciones Intramusculares , Esclerodermia Localizada/etiología , Esclerodermia Localizada/patología , Piel/efectos de los fármacos , Vitamina K 1/administración & dosificación , Vitaminas/administración & dosificación , Vitaminas/efectos adversosRESUMEN
BACKGROUND Morphea, also known as localized scleroderma, is a rare autoimmune connective tissue disease characterized by skin fibrosis. UVA1 phototherapy is an important asset in the reduction of clinical manifestations in morphea. There are studies claiming that UV light modulates the expression of some human endogenous retroviral sequences. The aim of this study was to determine if the expression of HERV-K10 gag element is lowered by UVA1 phototherapy in morphea, a disease in which such irradiation has a soothing effect. MATERIAL AND METHODS The expression levels of the HERV-K10 gag were assessed by real-time PCR (polymerase chain reaction) in peripheral blood mononuclear cells (PBMC) and skin-punch biopsies of healthy volunteers and 9 morphea patients before and after phototherapy. Additionally, correlations between the HERV-K10 gag expression and age, disease duration, the Localized Scleroderma Skin Severity Index (LoSSI), and antinuclear antibody (ANA) titers were assessed. RESULTS In PBMC, HERV-K10 gag mRNA was significantly elevated after UVA1 phototherapy compared to healthy controls. Most of the patients responded with an increased expression level of this sequence. However, we found no statistical evidence at this point that phototherapy indeed has an effect on the HERV-K10 gag expression (there were no statistical differences in PBMC of morphea patients before and after phototherapy). Similarly, there was no statistically relevant effect of the UVA1 on the expression of HERV-K10 gag in skin. CONCLUSIONS At this point, the effect of UVA1 phototherapy on the expression of HERV-K10 gag cannot be statistically confirmed.
Asunto(s)
Retrovirus Endógenos/efectos de la radiación , Productos del Gen gag/biosíntesis , Infecciones por Retroviridae/terapia , Esclerodermia Localizada/terapia , Terapia Ultravioleta/métodos , Adulto , Anciano , Estudios de Casos y Controles , Retrovirus Endógenos/genética , Retrovirus Endógenos/metabolismo , Femenino , Productos del Gen gag/genética , Productos del Gen gag/metabolismo , Humanos , Leucocitos Mononucleares/efectos de la radiación , Masculino , Persona de Mediana Edad , ARN Mensajero/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Infecciones por Retroviridae/sangre , Infecciones por Retroviridae/patología , Infecciones por Retroviridae/virología , Esclerodermia Localizada/sangre , Esclerodermia Localizada/patología , Esclerodermia Localizada/virología , Rayos UltravioletaRESUMEN
OBJECTIVE: To evaluate whether scleroderma patients who are double-positive for anti-interferon-inducible protein 16 (anti-IFI-16) antibodies and anticentromere (anti-CENP) antibodies are at increased risk for significant digital vascular events relative to patients positive for anti-CENP antibodies alone. METHODS: Sera from 165 scleroderma patients who tested positive for anti-CENP antibodies upon clinical evaluation were reassayed for both anti-CENP and anti-IFI-16 antibodies using enzyme-linked immunosorbent assay testing. Patients who were positive for anti-CENP antibodies alone were then compared to patients who were double-positive for both anti-IFI-16 and anti-CENP antibodies. The association between a history of significant digital vascular events (digital pits, ischemic digital ulcers, and/or gangrene) and double-positive antibody status was examined using chi-square tests. After completion of univariate analysis, multivariable analyses were done to adjust for clinically relevant covariates. RESULTS: Of the 165 anti-CENP antibody positive patients, 21 (12.7%) also had anti-IFI-16 antibodies. Patients who were double-positive for anti-CENP and anti-IFI-16 antibodies were more likely to have had digital pits, ischemic digital ulcers, and/or gangrene (P = 0.03). After adjustment for clinically relevant covariates (age, cutaneous subtype, disease duration, and smoking), double-positive patients remained at significantly higher odds of having severe Raynaud's phenomenon (odds ratio 3.5 [95% confidence interval 1.1-11.1]; P = 0.03). CONCLUSION: Scleroderma patients who are double-positive for antibodies recognizing CENP and IFI-16 are significantly more likely to have significant digital vascular events during the course of their disease. This study provides further evidence that anti-CENP and anti-IFI-16 antibodies are disease biomarkers that may be used for risk stratification of vascular events in scleroderma.
Asunto(s)
Anticuerpos Antinucleares/sangre , Autoanticuerpos/sangre , Dedos/irrigación sanguínea , Proteínas Nucleares/sangre , Fosfoproteínas/sangre , Esclerodermia Localizada/sangre , Esclerodermia Localizada/diagnóstico , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Estudios de Cohortes , Femenino , Dedos/patología , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Adulto JovenAsunto(s)
ATPasas Asociadas con Actividades Celulares Diversas/inmunología , Autoanticuerpos/inmunología , Proteínas Portadoras/inmunología , ADN Helicasas/inmunología , Polimiositis/inmunología , Esclerodermia Localizada/inmunología , Adulto , Autoanticuerpos/sangre , Azatioprina/uso terapéutico , Femenino , Humanos , Inmunosupresores/uso terapéutico , Polimiositis/sangre , Polimiositis/tratamiento farmacológico , Polimiositis/patología , Prednisolona/uso terapéutico , Esclerodermia Localizada/sangre , Esclerodermia Localizada/tratamiento farmacológico , Esclerodermia Localizada/patología , Resultado del TratamientoRESUMEN
A 28-year-old man with clinically and laboratory diagnosed anti-PL-12 anti-synthetase syndrome (AS) in 2009 developed cutaneous lupus lesions, discoid lupus lesions, and sclerodacytly with finger-tip ulcerations four years following his AS diagnosis. Laboratory tests including +ANA, +anti-dsDNA antibody, +anti-Smith antibody, and +anti-RNP antibody in 2014 confirmed the diagnosis of progression to an overlap syndrome including systemic lupus erythematosus. The patient now also has clinical findings (sclerodacytly, Raynaud phenomenon, finger-tip ulcerations) consistent with scleroderma overlap. In each stage of his evolving connective tissue disease, cutaneous findings have been central to the recognition and monitoring of his overlap syndromes.
Asunto(s)
Autoanticuerpos/sangre , Lupus Eritematoso Sistémico/complicaciones , Miositis/complicaciones , Esclerodermia Localizada/complicaciones , Adulto , Humanos , Lupus Eritematoso Sistémico/sangre , Masculino , Miositis/sangre , Esclerodermia Localizada/sangreRESUMEN
Localized scleroderma (LS) (morphea) is a chronic, inflammatory skin disease with unknown cause that progresses with sclerosis in the skin and/or subcutaneous tissues. Its pathogenesis is not completely understood. Oxidative stress is suggested to have a role in the pathogenesis of localized scleroderma. We have aimed to determine the relationship of morphea lesions with oxidative stress. The total oxidant capacity (TOC), total antioxidant capacity (TAC), paroxonase (PON) and arylesterase (ARES) activity parameters of PON 1 enzyme levels in the serum were investigated in 13 LS patients (generalized and plaque type) and 13 healthy controls. TOC values of the patient group were found higher than the TOC values of the control group (p < 0.01). ARES values of the patient group was found to be higher than the control group (p < 0.0001). OSI was significantly higher in the patient group when compared to the control (p < 0.005). Oxidative stress seems to be effective in the pathogenesis. ARES levels have increased in morphea patients regarding to the oxidative stress and its reduction. Further controlled studies are required in wider series.